Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela announces that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company’s stem cell product XSTEM® for the treatment and regeneration of skin defects, including difficult-to-heal (chronic) wounds. The patent, US 12,599,633, issues today and protects XSTEM in the United States until 7 June 2043.

“We are very pleased that the USPTO has now granted this patent, which provides important protection for XSTEM in one of the world’s largest pharmaceutical markets. The patent is the result of close and productive collaboration with the Burn Center in Linköping and confirms the strength of our stem cell technology. Difficult-to-heal wounds cause enormous suffering for patients and constitute a significant burden on healthcare systems globally, and we believe XSTEM has the potential to make a real difference for these patients”, says Xintela’s CEO Evy Lundgren-Åkerlund.